‘Developing Africa’s pharmaceutical sector crucial’
There is an urgent need to
develop the pharmaceutical sector in Africa to reduce the continent’s
dependence on imported pharmaceutical and medical products, so said Economic
Commission for Africa’s Soteri Gatera recently.
Gatera, Chief of the
Industrialization and Infrastructure Section at the ECA, said Africa bears a
disproportionate burden of disease with, for example, more than 70 percent of
the world’s HIV/AIDS cases and 90 percent of deaths due to malaria raising the
need to encourage local production of drugs.
“Non-communicable diseases are
also becoming increasingly prominent across the continent given the demographic
changes that are taking place,” he told participants in the meeting hosted by
the ECA, the African Union Commission and the United Nations Industrial
Development Organization (UNIDO).
Non-communicable diseases are
predicted to overtake infectious diseases as the leading causes of death in
Africa by 2030.
The situation is worsened by the
continent’s significant challenges in accessing high-quality pharmaceuticals,
exacerbating a continued high burden of disease.
The availability of essential
drugs in the public sector across the continent has been reported to be less
than 60 percent. The major factor being
that Africa is hugely dependent on imported pharmaceutical and medical
products.
It is estimated that more than 80
percent of ARVs used on the continent are imported from outside the continent
with 70 percent of the pharmaceutical and medical products market being served
by foreign imports.
“An international standard,
commercially viable pharmaceutical industry in Africa can contribute to
improved access to effective, safe and affordable essential medicines and
economic development,” Gatera said.
From the health perspective, he
added, a key potential benefit is to develop a source of quality assured
medicines across products including those for the pandemic diseases (HIV, TB
and malaria) as well as the broader range of essential medicines.
Through proximity of production,
resource-constrained regulators can properly oversee the manufacturing of
products produced in the region compared to the level of scrutiny that is
possible for distant suppliers, Gatera added further.
The immense need for drugs
presents a potential market opportunity for pharmaceutical companies on the
continent.
For example, he said, the current
number of persons on ARV treatment on the continent represents a market
opportunity of over US$ 1 billion.
This market will more than treble
over the next decade as more people are placed on ARV treatment and other uses
of ARVs are expanded.
The total pharmaceutical spending
for the continent in 2012 was estimated at US$ 18 billion and it is projected
to reach US$ 45 billion by 2020.
In addition to providing a secure
source of medicines and a potentially large market, local production of
pharmaceuticals will also advance industrial development, move the continent
towards sustainability of the health sector response, reduce external
dependency, facilitate stronger regulatory oversight to curtail counterfeit
products, enable production of drugs for diseases that primarily affect Africa,
improve the trade balance, create jobs and could serve as a catalyst to developing
a broader manufacturing and knowledge-based economy.
Soteri also enunciated a number
of measures taken by the AUC and its partners to promote the manufacture of
medicines in Africa in line with the accelerated industrialization initiative
for the continent’s socio-economic transformation.
“The untapped opportunities lend
themselves to a wide array of partnerships for the promotion of inclusive and
sustainable industrial development. The partnerships would create
higher-skilled jobs, build equitable societies and safeguard the environment,
while sustaining economic growth,” he said.
The workshop sought to validate
an ECA report titled Review of Policies and Strategies for the Pharmaceutical
Production Sector in Africa: Policy Coherence, Best Practices and Future
Prospective in which policies and strategies for the pharmaceutical sector in
Africa are reviewed with a view to assess the level of policy coherence,
capturing best practices and painting future prospects for the sector.
The report provides an overview
of the status of pharmaceutical production in Africa and identifies levels and
quality of production on the continent.
It is hoped, the final knowledge
product will influence African governments to take appropriate actions that
will transform the sector from being a coffer-drainer to a substantive
contributor to Africa’s GDP, concluded Gatera.
Comments
Post a Comment